Pharma BD Deal Intelligence

MannKind Corporation / scPharmaceuticals Inc.

2025 · Acquisition/Merger · $303M · Complete

MannKind Corporation agreed to acquire scPharmaceuticals Inc. for $5.35 per share in cash plus one non-tradable contingent value right worth up to $1.00 per share payable on specified regulatory and net sales milestones, for equity value of approximately $303 million at closing and up to approximately $360 million including CVRs. The transaction gives MannKind FUROSCIX, an FDA-approved on-body infuser delivering subcutaneous furosemide for fluid overload in adults with chronic heart failure and chronic kidney disease, establishing a cardiometabolic business alongside MannKind's orphan lung division. MannKind and Blackstone amended their strategic financing agreement to provide $175 million of additional funding. The acquisition closed October 7, 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals